Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Methotrexate 2Busulfan 2Alemtuzumab 2AP 1903 reagent 2visilizumab 1thymoglobulin 1fludarabine 1Transplantation 1Teriparatide 1Saline Solution 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Parathyroid Hormone 1Melphalan 1Heparin 1Fluorescent Antibody Technique 1Ficusin 1Etoposide 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Clofarabine 1Carmustine 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anemia, Aplastic × visilizumab × Clear all
NCT00720629 2014-07-18

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
8 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡